For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Grant revenue | - | 3,337 | 1,848 | 118,111 |
| Research and development | 1,611,167 | 1,008,839 | 1,638,917 | 1,912,213 |
| General and administrative | 1,819,245 | 1,637,591 | 1,480,319 | 1,593,671 |
| Total operating expenses | 3,430,412 | 2,646,430 | 3,119,236 | 3,505,884 |
| Loss from operations | -3,430,412 | -2,643,093 | -3,117,388 | -3,387,773 |
| Interest income, net | 134,784 | 118,664 | 150,669 | 178,027 |
| Other income | - | 77,500 | - | - |
| Foreign currency gain (loss) | 7,711 | -8,701 | -5,691 | -29,124 |
| Total other income | 142,495 | 187,463 | 144,978 | 148,903 |
| Net loss | -3,287,917 | -2,455,630 | -2,972,410 | -3,238,870 |
| Foreign currency translation | 9,014 | -5,180 | -1,117 | -1,681 |
| Total comprehensive loss | -3,278,903 | -2,460,810 | -2,973,527 | -3,240,551 |
| Basic EPS | -0.22 | -0.319 | -0.47 | -0.53 |
| Diluted EPS | -0.22 | -0.319 | -0.47 | -0.53 |
| Basic Average Shares | 14,685,448 | 7,704,755 | 6,372,938 | 6,083,329 |
| Diluted Average Shares | 14,685,448 | 7,704,755 | 6,372,938 | 6,083,329 |
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)